Evidence map›Paper›PMID 42904085›Full record

ArticleBlood neoplasia2026

Prognostic implications of

Yu-Hung Wang, Dorothée Selimoglu-Buet, Carmelo Gurnari, Matthew T Villaume, Somedeb Ball, Nathalie Droin, Hussein Awada, Andres Jerez, Andrius Zucenka, Chi-Yuan Yao and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yu-Hung WangEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Dorothée Selimoglu-BuetINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Matthew T VillaumeDivision of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN.
Somedeb BallDivision of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN.
Nathalie DroinINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Hussein AwadaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Andres JerezHaematology Department, University Hospital Vall d'Hebron, Barcelona, Spain.
Andrius ZucenkaHematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Chi-Yuan YaoDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Chien-Chin LinDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Hsin-An HouDivision of General Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wen-Chien ChouDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Hwei-Fang TienDivision of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Michael R SavonaDivision of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN.
Eric SolaryINSERM U1287, Gustave Roussy Cancer Center, Villejuif, France.
Kiran BattaEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Daniel H WisemanEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelomonocytic leukemia (CMML) is a heterogeneous myeloid neoplasm with highly variable prognosis.

Identifiers

PMID42904085
PMCPMC13681982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.